Eve Health Group initiates clinical study for Libbo film

· Eve Health Group has launched a pilot pharmacokinetic study for its 10 mg Libbo oral soluble film designed to treat erectile dysfunction.

· The company expects the trial data to provide essential tolerability and comparative baselines against traditional tablets.

· The clinical development forms part of a broader regulatory strategy to secure product commercialisation pathways in Australia.

Eve Health Group (ASX:EVE) has initiated a pilot pharmacokinetic clinical study to evaluate its 10 mg Libbo vardenafil oral soluble film for the treatment of erectile dysfunction.

The newly confirmed trial protocol is designed to compare the performance of this oral soluble film formulation against an existing Australian-registered reference vardenafil tablet.

The clinical trial will be conducted under strict fasted-state conditions utilising a cohort of healthy male subjects.

The company stated that the results from this preliminary evaluation are intended to directly inform the design of a subsequent pivotal bioequivalence study.

Following the announcement, the Eve Health Group share price was unchanged at $0.01.

The corporate strategy relies heavily on developing alternative drug delivery mechanisms to gain market share within the competitive consumer health and wellness sector.